**Question:** Definite markers for hepatoblastoma is-

A. AFP (alpha-fetoprotein) elevation
B. Bilirubin elevation
C. Hepatitis B surface antigen (HBsAg) positivity
D. Liver enlargement

**Core Concept:**
Hepatoblastoma is a rare malignant tumor of the liver in pediatric patients. It is classified into two main subtypes: fetal and exophytic, with fetal hepatoblastoma showing higher AFP (alpha-fetoprotein) production. AFP is a protein produced during fetal life and is primarily cleared by the liver. In hepatoblastoma, the tumor cells produce excessive AFP, which leads to its elevation in the blood.

**Why the Correct Answer is Right:**
The correct answer (A) is AFP elevation because hepatoblastoma is a fetal hepatic tumor that overproduces AFP. AFP is a protein produced during fetal life and cleared by the liver. When AFP production exceeds clearance, it leads to elevated blood AFP levels.

**Why Each Wrong Option is Incorrect:**

B. Bilirubin elevation (option B) can occur in various liver diseases, making it an unsuitable marker for hepatoblastoma diagnosis. Bilirubin is a product of heme catabolism and its elevation should not be considered specific to hepatoblastoma.

C. Hepatitis B surface antigen (HBsAg) positivity (option C) is a marker for Hepatitis B infection, not hepatoblastoma. Hepatoblastoma is unrelated to Hepatitis B virus infection, and detecting HBsAg is not useful in diagnosing this tumor.

D. Liver enlargement (option D) is a potential clinical sign and not a definitive marker for hepatoblastoma. Liver enlargement may occur due to various liver diseases, making it an unreliable diagnostic marker for hepatoblastoma.

**Clinical Pearl:**
Hepatoblastoma is a rare but potentially curable pediatric liver tumor. Monitoring AFP levels in serum is a valuable tool in diagnosing and managing hepatoblastoma, as its elevation indicates tumor burden and can guide treatment decisions.